The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens

Franco Maggiolo, Diego Ripamonti, Carlo Torti, Claudio Arici, Andrea Antinori, Eugenia Quiros-Roldan, Lorenzo Minoli, Laura Sighinolfi, Paola Nasta, Fredy Suter

Research output: Contribution to journalArticle

Abstract

Background: One of the more vigorous debates in the field of highly active antiretroviral therapy (HAART) is how to start it and what the optimal drug sequence is. Methods: A retrospective cohort analysis was performed. The aim was to evaluate which variables could influence the virological response to second-line genotypic-based HAART in patients with virological documented first-line HAART failure. A positive response was defined as a confirmed HIV RNA level

Original languageEnglish
Pages (from-to)923-929
Number of pages7
JournalAntiviral Therapy
Volume11
Issue number7
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens'. Together they form a unique fingerprint.

  • Cite this

    Maggiolo, F., Ripamonti, D., Torti, C., Arici, C., Antinori, A., Quiros-Roldan, E., Minoli, L., Sighinolfi, L., Nasta, P., & Suter, F. (2006). The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Antiviral Therapy, 11(7), 923-929.